Literature Study Review Of Vaccine Development Against African Swine Fever (ASF)
Abstract
Pig is one of the livestock commodities that is used to fulfill animal protein needs because it has a high percentage of carcass. In pig farming industrial, there are various problems, one of which is African Swine Fever which is very infectious and can cause sudden death on a large scale in an endemic area. Various efforts have been made, one of which is developing a vaccine against African Swine Fever. Vaccines are antigens in the form of microorganisms that are dead, still alive but attenuated, still intact or parts of which have been processed, in the form of toxin microorganisms that have been processed into toxoids, recombinant proteins.
This literature review aims to determine the development and effectiveness of vaccines in controlling the incidence of African Swine Fever. This literature study was obtained from searching and collecting from various reference sources using the Mendeley and Google Scholar applications. Based on a review of literature studies with literature, it was found that until now no vaccine has been found that can induce the formation of antibodies against African Swine Fever, but the type of vaccine is a live attenuated virus which has enormous potential to be developed into a vaccine because it is able to provide protection against homologous virus strains but still being developed to be able to provide cross-protection against heterologous viral strains.
Downloads
References
Mulumba-Mfumu, L.K, Goatley, L.C., Saegerman, C., Takamatsu, H.H., Dixon, L.K., 2015. Immunization of African indigenous pigs with Attenuated genotype I African swine fever virus OURT88/3 induces protection against challenge with virulent strains of genotype I. Transbound. Emerg. Dis. doi:http://dx.doi.org/10.1111/tbed.12303 [Epubaheadofprint].
Neilan, J.G., Zsak, L., Lu, Z., Burrage, T.G., Kutish, G.F., Rock, D.L., 2004. Neutralizing antibodies to African swine fever virus proteins p30, p54, and p72 are not sufficient for antibody-mediated protection. Virology 319,337-342.
Neilan, J.G., Zsak, L., Lu, Z., Kutish, G.F., Afonso, C.L., Rock, D.L., 2002. A novel swine virulence determinant in the left variable region of the african swine fever virus genome. J. Virol. 76(7), 3095-3104.b
Nurmoja I, Petrov A, Breidenstein C, Zani L, Forth JH., et al. 2017. Biological characterization of African swine fever virus genotype II strains from north-eastern Estonia in European wild boar. Transboundary and Emerging Diseases, 64 (6): 2034–2041.
O’Donnell V, Holinka LG, Gladue DP, Sanford B, Krug PW, Lu X, et al. 2015a. African swine fever virus Georgia isolate harboring deletions of MGF360 and MGF505 genes is attenuated in swine and confers protection against challenge with virulent parental virus. J Virol.;89(11):6048–56.
O’Donnell V, Holinka LG, Krug PW, Gladue DP, Carlson J, Sanford B, et al. 2015b. African swine fever virus Georgia 2007 with a deletion of virulenceassociated gene 9GL (B119L), when administered at low doses, leads to virus attenuation in swine and induces an effective protection against homologous challenge. J Virol.;89(16):8556–66.
O’Donnell V, Risatti GR, Holinka LG, Krug PW, Carlson J, Velazquez-Salinas L, et al. 2017. Simultaneous deletion of the 9GL and UK genes from the African swine fever virus Georgia 2007 isolate offers increased safety and protection against homologous challenge. J Virol.;91(1):e01760-16.
O'Donnell, V., Holinka, L.G., Sanford, B., Krug, P.W., Carlson, J., Pacheco, J.M., Reese, B., Risatti, G.R., Gladue, D.P., Borca, M.V., 2016. African swine
Copyright (c) 2022 Gregorius Ronaldo Mau Kuru, Yohanes T.R.M.R Simarmata, Maxs U.E Sanam
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.